Search Results
Your search for Matthew S matches 1058 pages
Showing 1 - 50Combination of Immunotherapies for Advanced HPV-Associated Cancers
In a single-center phase I/II trial reported in JAMA Oncology, Floudas et al found that the combination of the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin-12 antibody-drug conjugate PDS01ADC, and the bifunctional PD-L1/TGF-β inhibitor bintrafusp...
Locally Advanced Gastric Cancer: Adjuvant or Perioperative Therapy With D2 Resection
As reported in The Lancet Oncology by Zhang et al, final outcomes of the Chinese phase III RESOLVE trial showed improved overall survival with adjuvant S-1 and oxaliplatin (SOX) and perioperative SOX vs adjuvant capecitabine/oxaliplatin (CapOx) in patients with locally advanced gastric or...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
Tiragolumab Plus Atezolizumab/Bevacizumab in Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma
In a phase Ib-II study (MORPHEUS-Liver) reported in The Lancet Oncology, Finn et al found that the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab/bevacizumab improved objective response rate in patients with unresectable, locally advanced, or metastatic hepatocellular...
Addition of Cetuximab to Postoperative Radiotherapy in Intermediate-Risk Head and Neck Cancer
In a phase III trial (NRG/RTOG 0920) reported in Journal of Clinical Oncology, Machtay et al found that the addition of cetuximab to postoperative radiotherapy significantly improved disease-free survival—but not overall survival—in patients with completely resected, intermediate-risk, squamous...
Melanoma Among Adult Survivors of Childhood Cancer
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Rotz et al found that adult survivors of childhood cancers had a twofold increased risk of developing melanoma compared with the general population. Additionally, those with an invasive melanoma had a more...
Alpelisib Plus Fulvestrant in PIK3CA-Mutated, Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer After Previous Therapy
In a cohort of a phase II study (BYLieve) reported in The Lancet Oncology, Rugo et al found that the PI3Kα inhibitor alpelisib plus the hormone therapy fulvestrant showed activity in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer after disease...
Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL
Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Boston, discusses the primary endpoint evaluation of a phase II trial of the triplet regimen of acalabrutinib, venetoclax, and obinutuzumab in a population of patients with TP53-aberrrant chronic lymphocytic leukemia (CLL). The triplet...
Glofitamab or Rituximab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory DLBCL
As reported in The Lancet by Abramson et al, the phase III STARGLO trial has shown significantly improved overall survival with glofitamab plus gemcitabine/oxaliplatin vs rituximab plus gemcitabine/oxaliplatin in patients with transplant-ineligible relapsed or refractory diffuse large B-cell...
Hypofractionated vs Conventionally Fractionated Radiation After Implant-Based Breast Reconstruction
In a trial reported in JAMA Oncology, Julia S. Wong, MD, and colleagues found that hypofractionated postmastectomy radiation therapy did not improve outcomes in the physical well-being domain of the Functional Assessment of Cancer Therapy–Breast (FACT-B) assessment vs conventionally fractionated...
What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored by two speakers at the 2024 Pan Pacific Lymphoma Conference, sponsored by the University of...
High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem
Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications. Background Melanoma of the skin is the fifth most common cancer type in the...
Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy in Premenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer
As reported by Yen-Shen Lu, MD, PhD, and colleagues in the Journal of Clinical Oncology, final results of the phase II RIGHT Choice study indicate that ribociclib plus endocrine therapy significantly prolonged progression-free survival vs combination chemotherapy in premenopausal women with...
Noninferiority of Simple vs Radical Hysterectomy for Pelvic Recurrence in Low-Risk Cervical Cancer
As reported in The New England Journal of Medicine by Marie Plante, MD, of Centre Hospitalier Universitaire de Quebec, and colleagues, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in the frequency of pelvic recurrence in women with low-risk cervical...
Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is...
MRI-Guided Duration of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Anna van der Voort, MD, and colleagues found that magnetic resonance imaging (MRI) detected complete radiologic response after only three cycles of neoadjuvant chemotherapy in many patients with stage II to III HER2-positive...
Survival Benefit Emerges With Use of Dostarlimab-gxly Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced or recurrent endometrial cancer not only reduced the risk of disease progression but improved overall survival, particularly for the mismatch repair–deficient/microsatellite instability–high...
Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Barker et al found that induction treatment with vismodegib followed by concurrent treatment with vismodegib and curative-intent radiation therapy showed efficacy in patients with locally advanced unresectable basal cell carcinoma. ...
Cisplatin, Gemcitabine, and IMRT in Locally Advanced Vulvar Cancer
In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine, and intensity-modulated radiation therapy (IMRT) produced a high rate of complete pathologic response in patients with locally advanced vulvar...
Anti-CD19 CAR T-Cell Therapy for Richter Transformation
In a retrospective study reported in the Journal of Clinical Oncology, Kittai et al found that anti-CD19 chimeric antigen receptor (CAR) T-cell therapy showed activity in previously treated patients with Richter transformation. Study Details In the study, 69 patients who received CAR T-cell therapy ...
Gedatolisib Plus Palbociclib and Endocrine Therapy in HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in The Lancet Oncology by Layman et al, findings in dose-expansion groups of a phase Ib trial indicated activity of the pan-PI3K–mTOR inhibitor gedatolisib in combination with palbociclib and endocrine therapy in patients with hormone receptor (HR)-positive, HER2-negative advanced...
Crenolanib and Intensive Chemotherapy in Newly Diagnosed FLT3-Mutated AML
In a pilot study reported in the Journal of Clinical Oncology, Eunice S. Wang, MD, and colleagues found that the combination of crenolanib and intensive chemotherapy produced high response rates in adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Crenolanib is a...
Metastatic Castration-Resistant Prostate Cancer: LuPSMA vs Cabazitaxel
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, the Australian phase II TheraP trial has shown similar overall survival with lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) vs cabazitaxel in patients with prostate-specific membrane...
Adjuvant Treatment of Resected Melanoma: mRNA-Based Personalized Therapy Plus Immunotherapy
In the phase IIb KEYNOTE-942 trial reported in The Lancet, Jeffrey S. Weber, MD, PhD, and colleagues found that the addition of adjuvant mRNA-4157—a novel mRNA-based individualized neoantigen therapy—to pembrolizumab numerically improved recurrence-free survival in patients with completely resected ...
Use of Direct Oral Anticoagulant Agents in Active Cancer: Meta-Analysis
In a systematic review and meta-analysis reported in JACC: CardioOncology, Fujisaki et al found no significant differences among direct oral anticoagulant agents (DOACs) in the prevention of recurrent venous thromboembolism (VTE) associated with active cancer, whereas significant differences in...
Follicular Lymphoma: Long-Term Follow-up of Rituximab Dosing Strategies Among Patients With Low Tumor Burden
As reported in the Journal of Clinical Oncology by Brad S. Kahl, MD, and colleagues, long-term follow-up of the phase III Eastern Cooperative Oncology Group RESORT study (E4402) showed that rituximab maintenance did not improve overall survival vs rituximab retreatment in rituximab induction...
Real-World Data Show Impact of Immunotherapy in Populations Underrepresented in Lung Cancer Clinical Trials
New research published by Lee et al in JNCCN—Journal of the National Comprehensive Cancer Network found patients treated with first-line immunotherapy for advanced non–small cell lung cancer (NSCLC) had similar results in terms of overall survival, progression-free survival, and treatment duration, ...
Overall Survival With LuPSMA vs Cabazitaxel in Previously Treated Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, overall survival results from the Australian phase II TheraP trial showed no difference with lutetium-177–labeled PSMA-617 (LuPSMA) vs cabazitaxel in patients with metastatic castration-resistant prostate cancer and...
Modified vs Standard Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma
In a UK phase II trial (PRISM) reported in the Journal of Clinical Oncology, Vasudev and colleagues found that ipilimumab given every 12 weeks vs every 3 weeks in combination with nivolumab resulted in a significantly reduced rate of treatment-related grade ≥ 3 adverse events in treatment-naive...
Blood-Based Testing for Multicancer Early Detection
In a prospective cohort study (PATHFINDER) reported in The Lancet, Deb Schrag, MD, MPH, FASCO, and colleagues evaluated the performance of blood-based testing for multicancer early detection in adults without signs or symptoms of cancer. As stated by the investigators, “Multicancer early detection ...
Do Low- and Moderate-Grade Adverse Events Affect Rates of Treatment Discontinuation in CLL?
In an analysis from the phase III ECOG/ACRIN E1912 trial in chronic lymphocytic leukemia (CLL) published in the Journal of Clinical Oncology, O’Connell et al found that grade 1 and 2 adverse events were significant contributors to patient-reported side-effects bother, with grade 2 events being...
Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer
Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...
Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting
The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...
Tisotumab Vedotin–Based Combinations in Advanced Cervical Cancer
In a phase Ib/II study (innovaTV 205/GOG-3024/ENGOT-cx8) reported in the Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, and colleagues found that tisotumab vedotin-tftv combined with carboplatin or pembrolizumab showed activity in both treatment-naive and previously treated patients with ...
Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma
In a study reported in the Journal of Clinical Oncology, Mandelker et al found that pancreatic acinar cell carcinoma was associated with a high prevalence of BRCA2 germline pathogenic variants and genomic features of homologous recombination deficiency (HRD). The study involved somatic and germline ...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
Atezolizumab With or Without Radiotherapy in Advanced Penile Cancer
In the Dutch single-institution phase II PERICLES trial reported in the Journal of Clinical Oncology, de Vries et al found atezolizumab produced activity in patients with advanced squamous cell carcinoma of the penis. Study Details In the study, 32 patients enrolled at The Netherlands Cancer...
Stereotactic Radiosurgery Before Resection of Brain Metastases From Solid Tumors
In a study reported in JAMA Oncology, Prabhu et al identified outcomes and associated risk factors among patients receiving stereotactic radiosurgery (SRS) prior to resection of brain metastases from solid tumors. Study Details The study involved data from an international multicenter cohort...
Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial
As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit with osimertinib vs placebo in patients with resected EGFR-mutant non–small cell lung cancer (NSCLC)....
Epcoritamab-bysp in Treatment of Relapsed or Refractory B-Cell Lymphomas
On May 19, 2023, epcoritamab-bysp was granted accelerated approval by the U.S. Food and Drug Administration for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two ...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
Pembrolizumab/Olaparib vs Next-Generation Hormonal Agents in Previously Treated Patients With Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Emmanuel S. Antonarakis, MD, and colleagues, the phase III KEYLYNK-010 trial has shown no improvement in survival outcomes with pembrolizumab/olaparib vs a next-generation hormonal agent (abiraterone or enzalutamide) in previously treated patients...
Late-Onset Memory Impairment in Adult Survivors of Childhood Cancer
In an analysis reported in JAMA Network Open, Phillips et al found that adult survivors of childhood cancer were at an increased risk of new-onset memory impairment vs their siblings. Modifiable factors associated with increased risk of impairment among survivors were identified. Study Details The...
S-1 Chemoradiotherapy for Older Patients With Inoperable Esophageal Squamous Cell Carcinoma
In a Chinese phase III trial reported in JAMA Network Open, Wang et al found that oral S-1 chemotherapy given with simultaneous integrated boost radiotherapy (SIB-RT) and following SIB-RT improved overall survival in patients aged 70 or older with inoperable esophageal squamous cell carcinoma....
Adagrasib in Treatment of KRAS G12C–Mutated Advanced Solid Tumors
As reported in the Journal of Clinical Oncology by Tanios S. Bekaii-Saab, MD, and colleagues, findings in the phase II cohort of the KRYSTAL-1 trial showed activity of adagrasib in patients with KRAS G12C–mutated advanced solid tumors. As noted by the investigators, the KRAS G12C inhibitor...
Risk of Dementia and Mortality With BCG Vaccine in Non–Muscle-Invasive Bladder Cancer
In a study reported in JAMA Network Open, Weinberg et al found that receipt of the bacillus Calmette-Guérin (BCG) vaccine in patients with non–muscle-invasive bladder cancer was associated with a lower risk of Alzheimer’s disease and related dementias—as well as a lower risk of mortality—compared...
New Fellows of the American Society of Clinical Oncology
The FASCO distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Recipients will be recognized during the Opening Session of the Annual Meeting on Saturday, June 3. The following members are being recognized in 2023: Kerin Adelson, MD,...
New Fellows of the American Society of Clinical Oncology (FASCO)
The FASCO distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Recipients will be recognized during the Opening Session of the Annual Meeting on Saturday, June 3. The following members are being recognized in 2023: Kerin Adelson, MD,...
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancer
In a single-institution study reported in JACC: CardioOncology, Stephanie Feldman, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors,...
Potential Utility of Polygenic Risk Scores in Cancer Screening in the United Kingdom
In a modeling study reported in The Lancet Oncology, Huntley et al found that the extension of UK cancer screening programs for breast, prostate, and colorectal cancers to a polygenic risk score (PRS)-defined high-risk group of patients with cancer may improve cancer case detection and avoidance of ...
